Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, is pioneering computational pathology for pharmaceutical research and diagnostics. Its proprietary "Explainable AI" platform draws on research from Fraunhofer Society, Charité, and TU Berlin to overcome the typical "black-box" problem of AI in pathology. Aignostics' focus lies on developing bespoke AI models for clinical trials and CDx development.
Year of investment: 2020; BIVF Board Representative: Alexander Ehlgen
Brainomix, Ltd. focuses on imaging software for neurological and cerebrovascular diseases and developed a software tool (e-ASPECTS) for the automated analysis of CT scans to detect early ischemic changes in the brain of patients with clinical signs of stroke. Brainomix is a spin-out from the University of Oxford, UK.
Year of investment: 2018; BIVF Board Representative: Frank Kalkbrenner
Bodyport’s mission is to prevent and ultimately eliminate heart disease by empowering every person with high quality, actionable health information in their home.
Year of investment: 2019; BIVF Board Representative: Debbie Lin
Dopavision GmbH is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated while using a smartphone. The technology projects a light stimulus from a screen (e.g., a smartphone) into the eye to activate a neurotransmitter cascade which influences the correct development of the eyeball and thereby correct vision. Dopavision is headquartered in Berlin, Germany.
Year of investment: 2018; BIVF Board Representative: Oliver Reuß
Perfood analyzes glycemic responses to meals, activity, symptoms, medication and gut microbiome on the basis of machine learning algorithms. This results in a pipeline of digital therapeutics based on personalized low-glycemic diet. At the same time, Perfood builds up a rich dataset for phenotyping.
Year of investment: 2020; BIVF Board Representative: Oliver Reuß
Wellth, Inc. applies behavioral economics through a mobile first, financial incentive focused behavior change platform to achieve better adherence, engagement, and health. The solution serves the most common chronic conditions. Wellth is headquartered in Brooklyn, NY.
Year of investment: 2018; BIVF Board Representative: Debbie Lin